Stem cell-derived exosomes for acute liver failure: Mechanisms, therapeutic potential, and translational challenges
Hepatobiliary Communications · 2027-09 · 2 (1) · 100016
DOI: 10.1016/j.hbc.2026.100016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatobiliary Communications, 2027-09. Verfasst von Jia Liu und 2 weiteren Autor:innen. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Acute liver failure (ALF) is a rapidly progressive and life-threatening syndrome marked by massive hepatocyte loss, systemic inflammation, and high short-term mortality, with treatment still largely limited to supportive care and liver transplantation. Although triggered by diverse etiologies, ALF converges on common pathogenic mechanisms, including inflammatory amplification, dysregulated innate immunity, oxidative stress, regulated cell death, microenvironmental disruption, and insufficient hepatic regeneration. These interconnected processes provide the mechanistic basis for emerging targeted therapies. Among them, stem cell-derived exosomes have gained increasing attention as a promising cell-free therapeutic strategy. Carrying bioactive cargos such as microRNAs, proteins, and lipids, these vesicles recapitulate key paracrine effects of parent stem cells and exert multi-level protective functions in preclinical ALF models. They suppress inflammation driven by hepatic macrophages, including Kupffer cells and monocyte-derived macrophages, inhibit hepatocyte death programs, attenuate oxidative stress, preserve mitochondrial and hepatic microenvironmental integrity, and promote the resolution of necroinflammation and regenerative repair. However, their clinical translation remains hindered by heterogeneity in experimental models, insufficient standardization of isolation and manufacturing, uncertainty in dosing and delivery, and unresolved regulatory challenges. Overall, stem cell-derived exosomes represent a biologically compelling and potentially transformative therapeutic approach for ALF, but further mechanism-guided optimization, standardized production, and rigorous translational studies are required for clinical application.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Xin, Y., & Bi, Y. (2027). Stem cell-derived exosomes for acute liver failure: Mechanisms, therapeutic potential, and translational challenges. Hepatobiliary Communications, 2(1), 100016. https://doi.org/10.1016/j.hbc.2026.100016
Vancouver
Liu J, Xin Y, Bi Y. Stem cell-derived exosomes for acute liver failure: Mechanisms, therapeutic potential, and translational challenges. Hepatobiliary Communications. 2027;2(1):100016. doi:10.1016/j.hbc.2026.100016
BibTeX
@article{Liu2027,
author = {Liu, Jia and Xin, Yongning and Bi, Yanzhen},
title = {Stem cell-derived exosomes for acute liver failure: Mechanisms, therapeutic potential, and translational challenges},
journal = {Hepatobiliary Communications},
year = {2027},
volume = {2},
number = {1},
pages = {100016},
doi = {10.1016/j.hbc.2026.100016}
}
EUVIMED